Le LÚzard
Classified in: Health
Subjects: AWD, SVY

EVERSANA CONSULTING Named a Top Consulting Firm in Asia Pacific Region for the Second Consecutive Year


SINGAPORE and CHICAGO, Feb. 22, 2024 /PRNewswire/ -- EVERSANA«, a leading provider of commercialization services to the life science industry, today announced its strategic consulting arm EVERSANA« CONSULTING has been named a Vault Top Consulting Firm in the Asia Pacific Region for the second consecutive year.

EVERSANA CONSULTING ranks number 20 on the annual list of top firms in the region. The firm has seen significant growth throughout the region in the past three years, including expansion across multiple markets including Singapore, Japan, Australia, South Korea, and India. The company continues to attract top talent to serve the growing needs of clients throughout the area.

"Our team ranks among the best at understanding the challenges pharmaceutical companies face in bringing therapies to the region, but also at helping companies understand what commercialization should look like worldwide," said Jim Lang, CEO at EVERSANA. "To be honored for two consecutive years by Vault in the Asia Pacific region is an honor, but delighting our clients every day matters even more."

Vault's rankings are based on exclusive insider information from verified employees in the consulting industry. Each year, Vault surveys thousands of consulting professionals. From these results, top consulting firms are ranked based on prestige, quality of life, and overall best place to work across several categories.

EVERSANA CONSULTING ranked number 10 on the annual list as "A Best Consulting Firm for Formal Training," and number 13 as "A Best Firm for Compensation" in the Asia Pacific region. Vault's Firsthand Findings note that "This is an entrepreneurial organization with a fantastic culture." To view the profile, click here.

The accolade comes just weeks after the firm's North American team was also named a top consulting organization for 2024.

EVERSANA CONSULTING is the global consulting services arm of EVERSANA, serving a broad range of large and small biopharma, med tech and digital therapeutics companies. The team combines business strategy, launch excellence and commercial execution to provide end-to-end advisory services to clients. To learn more, visit eversanaconsulting.com.

About EVERSANA«
EVERSANA« is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X.

Media:
Matt Braun
[email protected]
+1 414-975-8831

SOURCE EVERSANA


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO OháSang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO« (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: